Significant Overall CR Improvement Seen in DLBCL Patients Reported Following Zilovertamab Vedotin Plus R-CHP

Merck’s investigational antibody–drug conjugate that targets receptor tyrosine kinase–like orphan receptor 1 (ROR1), zilovertamab vedotin, used in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) for the treatment of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) achieved a 100% (n=15) complete response (CR) rate, according to results presented at the 66th ASH Annual Meeting and Exposition, in San Diego, CA, and simultaneously published in Blood.¹

Researchers presented data on the phase 2 waveLINE-007 trial (NCT05406401) that is evaluating zilovertamab vedotin (MK-2140) in combination with R-CHP in patients with previously untreated DLBCL.

As of data cutoff, 36 patients were enrolled in the study to receive zilovertamab vedotin plus R-CHP intravenously on day 1 of each 21-day cycle for up to 8 cycles.

The efficacy results showed a CR was achieved in combination with R-CHP in 100% (n=15) of patients receiving the 1.75-mg/kg dose of zilovertamab vedotin (95% confidence interval [CI], 78.2-100.0), 93.3% (n=14) of patients receiving the 2.0-mg/kg dose (95% CI, 68.1-99.8), and 100% (n=6) of patients receiving the 2.25-mg/kg dose (95% CI, 54.1-100.0).

At a median follow-up of 17.6 months, the total CR rate at the end of treatment was 97.2% (95% CI, 85.5-99.9).

Based on the data, the recommended zilovertamab vedotin dose was determined to be 1.75 mg/kg.

Reference

1. Ozcan M, Barca EG, Kim TM, et al. Waveline-007: dose escalation and confirmation, and efficacy expansion trial of zilovertamab vedotin in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab in patients with diffuse large B cell lymphoma. Blood. 2024;144 (suppl 1):578-580.